Targeting Polyamines using DFMO in Persons with Type 1 Diabetes: A Randomized Double-Masked Placebo-Controlled Phase I/II Study to Evaluate the Safety Tolerability and Initial Pharmacodynamics of Multiple Ascending Doses



Study Overview

The purpose of this study is to determine if different doses of a drug known as DFMO have an effect on reducing the amount of stress that is experienced by the body's beta cells and preserves residual c-peptide.


Study Description

The purpose of this study is to determine if different doses of a drug known as DFMO have an effect on reducing the amount of stress that is experienced by the body's beta cells and preserves residual c-peptide.

Additional Information:

Participants will be paid for their participation.



Research Study Identifier: TX4823
ClinicalTrials.gov Identifier: NCT1411735324
Principal Investigator: Linda DiMeglio, MD


Currently Recruiting

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.